Bernard Gilly, GenSight CEO (Eric Piermont/AFP via Getty Images)
June 30, 2021 07:37 AM EDTUpdated 11:00 AM
R&D
Cell/Gene Tx

Gen­Sight's gene ther­a­py mys­tery con­tin­ues, as pa­tients im­prove in an­oth­er failed tri­al

Jason Mast

Editor

A three-year-old med­ical mys­tery took its lat­est turn Thurs­day, when Gen­Sight re­leased da­ta from its third tri­al for a rare form of blind­ness: Once again …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times